Immatics Announces Pricing of $175 Million Public Offering
January 17, 2024 20:30 ET
|
https://immatics.com/
Houston, Texas and Tuebingen, Germany, January 17, 2024 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T...
Immatics Announces Proposed Public Offering
January 17, 2024 16:01 ET
|
https://immatics.com/
Houston, Texas and Tuebingen, Germany, January 17, 2024 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T...
Adagene Presents Interim Results Reinforcing Best-in-Class Profile of Masked anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC)
January 16, 2024 17:01 ET
|
Adagene Inc.
- Data from first tranche of MSS CRC patients treated with ADG126 10 mg/kg every three weeks (Q3W) in dose expansion showed clinical benefit including confirmed responses at higher, more frequent and...
Eye Melanoma Market Size Worth USD 9.56 Billion in 2032 | Emergen Research
January 11, 2024 08:57 ET
|
Emergen Research
Vancouver, Jan. 11, 2024 (GLOBE NEWSWIRE) -- The global eye melanoma market size was USD 4.35 billion in 2022 and is expected to register a revenue CAGR of 8.3% during the forecast period. Eye...
Nasal Allergy Treatment Market: Anticipating a Reach of US$ 21.4 Billion by 2032, Projected for Substantial Growth at a 4% CAGR from 2022 to 2032 | Persistence Market Research
January 10, 2024 09:48 ET
|
Persistence Market Research
New Yor, Jan. 10, 2024 (GLOBE NEWSWIRE) -- The global nasal allergy treatment market is poised for steady growth, driven by the increasing prevalence of allergic rhinitis, a chronic inflammatory...
Curex Revolutionizing Allergy Immunotherapy with Telehealth and Home-Delivered Allergy Drops
December 28, 2023 18:00 ET
|
Curex
New York,NY, Dec. 28, 2023 (GLOBE NEWSWIRE) -- Allergy sufferers looking to treat their allergies without the pain and inconvenience of weekly visits to their doctor now have an ally in an at-home...
Immunotherapy Targeting Mesothelin: A Comprehensive 2023 Pipeline Review
December 14, 2023 05:43 ET
|
Research and Markets
Dublin, Dec. 14, 2023 (GLOBE NEWSWIRE) -- The "Mesothelin-Targeted Immunotherapy Pipeline Review" report has been added to ResearchAndMarkets.com's offering. A groundbreaking review of...
Immuno-Oncology Research Advances: 2023 CCR8-Targeted Antibody Immunotherapy Pipeline Insights
December 14, 2023 05:38 ET
|
Research and Markets
Dublin, Dec. 14, 2023 (GLOBE NEWSWIRE) -- The "CCR8-Targeted Antibody Immunotherapy Pipeline Review" report has been added to ResearchAndMarkets.com's offering. A novel research publication...
EnGeneIC granted FDA “Fast-Track” Designation for Novel Armed Nanocell Drug Conjugate (ANDC) Pancreatic Cancer Therapeutic
December 07, 2023 19:51 ET
|
EnGeneIC
EneneIC has been granted Fast Track designation for use of its novel Armed Nanocell Drug Conjugate (ANDC) in PDAC patients.
United States Liver Cancer Therapeutics Research Report 2023: Markets, Competition, Forecast and Opportunities, 2018-2028
December 07, 2023 11:08 ET
|
Research and Markets
Dublin, Dec. 07, 2023 (GLOBE NEWSWIRE) -- The "United States Liver Cancer Therapeutics Market, Competition, Forecast and Opportunities, 2018-2028" report has been added to ResearchAndMarkets.com's...